OrbusNeich’s Genous stent was found to be safe when combined with a ten-day dual antiplatelet therapy (DAPT) in the multicentre study.
The Genous stent uses the company’s patented endothelial progenitor cell (EPC) capture technology to promote natural healing of the vessel wall following the implantation.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The multicentre trial with Genous stent involved 49 patients with de novo lesions in vessels, and showed that 55.1% of patients were diagnosed with multivessel disease.
University of Rome Tor Vergata professor Giuseppe Sangiorgi said in the study they observed only one case of stent thrombosis at 26 days in a patient who had previously undergone percutaneous coronary intervention and stenting in the mid-left anterior descending artery with a bare metal stent.
”This supports the case for Genous as a safe and effective treatment alternative for patients who cannot comply with a four-week-or-longer course of DAPT due to either bleeding risk or the need for a near-term invasive non-cardiac procedure," Sangiorgi added.
Earlier multiple clinical studies reported that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
